Skip to Main Content
<< Back | Return to Main COMAR Search Page

6 records match your request.

FileAbstract
10.13.03.00.htm 10.13.03.00. Title 10 MARYLAND DEPARTMENT OF HEALTH Subtitle 13 DRUGS Chapter 03 Guidelines for Co-Prescribing Opioid Overdose Reversal Drugs Authority: Health-General Article, §2-104(b) 13-3501, and 13-3502, Annotated Code of Maryland
10.13.03.01.htm 10.13.03.01. 01 Scope.. This chapter applies to all licensed health care practitioners who may prescribe an opioid overdose reversal drug to an individual who:A. May be at an elevated risk of experiencing an opioid overdose including, but not limited to, an individual who:1) Is receiving an opioid for chronic pain;. 2) Is receiving an opioid and a prescription for a benzodiazepine; or. 3) Has an opioid use disorder; or. B. Resides or spends time with an individual who:.
10.13.03.02.htm 10.13.03.02. 02 Definitions.. A. In this chapter, the following terms have the meanings indicated.. B. Terms Defined.. 1) “Co–prescribed” means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at an elevated risk of overdose.2) “Department” means the Maryland Department of Health.. 3) “Monitored prescription drug” means a prescription drug that contains a Schedule II, Schedule III
10.13.03.03.htm 10.13.03.03. 03 General Provisions.. A. When determined appropriate by the prescribing licensed health care provider, targeted patient populations may be co-prescribed an opioid overdose reversal drug, if the individual is at an elevated risk of experiencing an opioid overdose by virtue of belonging to one or more categories of the targeted patient population.B. Responsibilities of the Prescribing Licensed Health Care Provider.. 1) Risk Monitoring.. a) It is suggested that t
10.13.03.04.htm 10.13.03.04. 04 Additional Guidelines.. The Secretary may make the following additional clinical guidance available on the Department’s website:A. Any available opioid overdose reversal drug formulations, corresponding prescribing templates, and any standing order for these drugs; andB. Any other applicable information deemed necessary by the Secretary..
10.13.03.9999.htm 10.13.03.9999. Administrative History Effective date: June 17, 2019 (46:12 Md. R. 544).
<< Back | Return to Main COMAR Search Page